Phase I trials are a critical first step in the study of novel cancer therapeutic approaches. Their primary goals are to identify the recommended dose, schedule and pharmacologic behavior of new agents or new combinations of agents and to describe the adverse effects of treatment. In cancer therapeutics, such studies have particular challenges. Due to the nature of the effects of treatment, most such studies are conducted in patients with advanced malignancy, rather than in healthyvolunteers. Further, the endpoints of these trials are usually measures adverse effects rather than molecular target or anti-tumor effects. These factors render the design, conduct, analysis and ethical aspects of phase I cancer trials unique. As the only comprehensive book on this topic, Phase ICancer Clinical Trials is a useful resource for oncology trainees or specialists interested in understanding cancer drug development. New to this edition are chapters on Phase 0 Trials and Immunotherapeutics, and updated information on the process, pitfalls, and logistics of Phase I Trials
1. Introduction; 2. Preclinical Data and Requirements; 3. Phase 0 Clinical Trials; 4. Basics of Phase I Design: First-in-man Studies; 5. Ethical Issues in First-in-human Phase I Cancer Trials; 6. Phase I Trials in Special Populations and Circumstances; 7. Phase I Trials of Immunotherapeutics; 8. Statistical Designs for First-in-human Phase I Trials; 9. Writing the Protocol; 10. Practical Aspects of Pharmacokinetics and Pharmacodynamics; 11. Process, Pitfalls, and Logistics of Phase I Trials; 12. Reporting and Interpreting Results; Appendix: Useful Web Resources;
Komentarze (0)
Chwilowo nie możesz polubić tej opinii
Zgłoś komentarz
Czy jesteś pewien, że chcesz zgłosić ten komentarz?
Zgłoszenie wysłane
Twój komentarz został wysłany i będzie widoczny po zatwierdzeniu przez moderatora.